Intranasal esketamine

PreclinicalSmall molecule

Intranasal esketamine is one of 45 small molecule programs targeting Autism Spectrum Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autism Spectrum DisorderActive, not recruiting

Autism Spectrum DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Autism Spectrum Disorder

#DrugCompanyPhaseTrials

Buspar

Bristol-Myers Squibb

Approved

4 2

Namenda

AbbVie

Approved

3 3

Lioresal

Epidiolex

Aricept

Marinol

Abilify

2 8

Neurontin

VViatris Specialty LLC

Approved

2 9

Strattera

MMap77

Approved

1 10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Autism Spectrum Disorder

NCT07324057

Clinical

Trials by Indication[1]

Esketamine1 trial

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

Completed·PPsych Atlanta··NCT04856124·10 enrolled

Cardiac Repolarization1 trial

A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02737605·62 enrolled

Treatment Resistant Depression1 trial

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02918318·202 enrolled

Autism Spectrum Disorder1 trial

The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavioral Changes in Children With Autism Spectrum Disorder

Not yet recruiting·SSun Fei·N/A·NCT07324057·234 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Intranasal esketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intranasal esketamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intranasal esketamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Johnson & Johnson

Intranasal esketamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Esketamine1 trial

Cardiac Repolarization1 trial

Treatment Resistant Depression1 trial

Autism Spectrum Disorder1 trial

References

Drug Info

Quick Facts

Related News